|
|||||||
 |
If you live in the U.K. and suffer from ankylosing spondylitis, you had better live in Scotland. The National Institute for Health and Clinical Excellence (NICE), the national drug rationing body, has ruled that infliximab, has ruled that the drug is not cost effective. At £15,000 ($30,000) a year it is £5,000 ($10,000) a year more than [...] Arthritis Awareness Week is March 29th to April 4th, an initiative of Arthritis Australia, and is a time of promotional and educational activities, held around the country, to raise awareness about arthritis, its effects, and the various treatment and management options available. Arthritis Australia hopes that these activities will make all Australians aware that arthritis is not [...] The FDA ordered that the class of drugs known as TNF blockers carry a warning on the packaging that their use carries the risk of developing a potentially deadly fungal disease called histoplasmosis. [...] A global team of researchers, led by Professor Matthew Brown, from the University of Queensland’s Diamantina Institute for Cancer, Immunology and Metabolic Medicine, has discovered that there is a genetic relationship between ankylosing spondylitis (AS) and Crohn’s disease. The study was published in the current issue of Nature Genetics. AS is a form of arthritis that causes [...] Spondylarthritis (SpA) represents a group of arthritis diseases that have similar symptoms such as inflammatory back pain and inflammation at sites where tendons attach to bone. It includes ankylosing spondylitis, psoriatic arthritis, inflammatory bowel-disease-related arthritis, reactive arthritis and undifferentiated spondylarthritides (uSpA). Since Chlamydia trachomatis or Chlamydia pneumoniae frequently cause reactive arthritis, a new study led by John [...] |
  
|
|||||
|
Copyright © 2010 Current Arthritis News and Research - All Rights Reserved
|
|||||||
Recent Comments